Visit main University website

Find MND Biomarker

Find MND Biomarker

Find MND Biomarker

Find MND Biomarker

Welcome to FindMNDBiomarker, an integrative database that consolidates the proteomic findings in brain tissue and biofluids (CSF and blood) from patients with motor neuron disease (also known as amyotrophic lateral sclerosis). FindMNDBiomarker is designed for users to quickly assess whether their proteins of interest have been identified in other cohorts and biosamples from patients with MND/ALS.

Purpose: The goal of this search platform is to facilitate the comparison and discovery of proteins that may serve as promising and reproducible biofluid biomarkers of brain-specific changes in MND/ALS and to identify markers that should be further targeted for analyses and validation.

Using this database: Searches can be performed by entering the protein UniProt IDs, names and sample types into the relevant search term box using free text entry. For example, entering ‘NEFL’ will generate a list of all publications in which NEFL was identified to be significantly dysregulated.

A searchable and filterable table is provided with the following columns:

  • Name: Gene name corresponding to the UniProt ID
  • UniProt ID: UniProt accession number
  • Publication: Study Reference
  • Condition: e.g.ALS – Control, ALS Fast – ALS Slow
  • Sample Type: Sample type used (Abbreviations: SMNs, single motor neurons; AH, anterior horn; PH, posterior horn)
  • Regulation: Direction of change (upregulated or downregulated)
  • Cohorts: Cohort size used for each study
  • Average age at onset ± standard deviation/age range: Average age at onset of ALS cohorts with standard deviation or age range (if provided by publication)
  • Average age at collection ± standard deviation/age range: Average age at collection of ALS cohorts with standard deviation or age range (if provided by publication)
  • Average PMI (range) (hours): Average postmortem interval with range (if provided by tissue studies)

To cite this database: Further details and application of this search tool are described in our manuscript “title” that can be located with this DOI: _____

Contact: For help contact rachel.tan1@sydney.edu.au
Sort by:
Total Records Found: 3275, showing 100 per page
Biomarker NameUniProt IDPublicationDisease GroupComparator GroupSample TypeRegulationCohortsAverage age at onsetAverage age at collectionAverage PMI
CALY Q9NYX4 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CALU O43852 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CALU O43852 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
CALR P27797 Guise et al. 2024 ALS Control Spinal cord (SMNs) Down 3 ALS, 3 control N/A 69.3 9.2
CALR P27797 Filareti et al. 2017 Late ALS Early ALS PBMCs Up 16 Early-ALS, 16 Late-ALS N/A 50 ± 5 (Early-ALS), 80 ± 4 (Late-ALS) N/A
CALR P27797 Leoni et al. 2019 BO-ALS LO-ALS PBMCs Down 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS) N/A N/A
CALR P27797 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
CALM3 P62158 Seyfried et al. 2018 ALS Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
CALM3 P62158 Zubiri et al. 2018 ALS fast (late stage) ALS slow (late stage) Plasma Up 6 ALS-fast, 6 ALS-slow 61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow) N/A N/A
CALM3 P62158 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CALM3 P62158 Zubiri et al. 2018 Late ALS (ALS fast cohort) Early ALS (ALS fast cohort) Plasma Down 6 ALS-fast, 6 ALS-slow 61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow) N/A N/A
CALM3 P62158 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
CALM1 P0DP23 Englen-Lee et al. 2017 ALS Control Spinal cord (PH & AH) Down 10 ALS, 10 control 57.6 ± 10.9 62.6 ± 10.6 N/A
CALM1 P0DP23 Guise et al. 2024 ALS Control Spinal cord (SMNs) Down 3 ALS, 3 control N/A 69.3 9.2
CALD1 Q05682 Oeckl et al. 2020 ALS Control Spinal cord Up 8 ALS, 7 control N/A 59 (52-61) 36 (24-90)
CALB2 P22676 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CALB2 P22676 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
CADPS Q9ULU8 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
CADM4 Q8NFZ8 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
CADM4 Q8NFZ8 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CADM3 Q8N126 Collins et al. 2015 ALS Control CSF Down 90 ALS, 80 control N/A N/A N/A
CADM1 Q9BY67 Bereman et al. 2018 ALS Control CSF Down 33 ALS, 30 control N/A N/A N/A
CACYBP Q9HB71 Iridoy et al. 2018 ALS Control Spinal cord (AH) Down 9 ALS, 8 control 57.6 62.8 N/A
CACNG8 Q8WXS5 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CACNA2D3 Q8IZS8 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CACNA2D1 P54289 Leoni et al. 2019 BO-ALS LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
CACNA2D1 P54289 Bereman et al. 2018 ALS Control CSF Down 33 ALS, 30 control N/A N/A N/A
CACHD1 Q5VU97 Zhou et al. 2023 BO-ALS Control CSF Up 4 BO-ALS, 5 SO-ALS, 5 control 63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS) 64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS) N/A
CA2 P00918 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
CA1 P00915 Iridoy et al. 2018 ALS Control Spinal cord (AH) Up 9 ALS, 8 control 57.6 62.8 N/A
CA1 P00915 Berrone et al. 2023 ALS Control Plasma Down 16 ALS, 8 control 62 ± 13 (sALS & fALS) 64 ± 11 (sALS & fALS) N/A
CA1 P00915 Bereman et al. 2018 ALS Control Plasma Up 33 ALS, 30 control N/A N/A N/A
CA1 P00915 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
C9 P02748 Leoni et al. 2019 BO-ALS LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
C9 P02748 Xu et al. 2018 ALS Control Plasma Up 42 ALS, 18 control N/A 61.8 ± 9.6 N/A
C9 P02748 Chen et al. 2016 ALS Control CSF Down 35 ALS, 10 control N/A 52.7 ±12.13 N/A
C9 P02748 Vu et al. 2023 ALS fast ALS slow CSF Up 6 ALS-fast, 5 ALS-slow 54.3 (ALS-fast), 43.4 (ALS-slow) 55.3 (ALS-fast), 52.2 (ALS-slow) N/A
C8G P07360 Vu et al. 2023 ALS fast ALS slow CSF Up 6 ALS-fast, 5 ALS-slow 54.3 (ALS-fast), 43.4 (ALS-slow) 55.3 (ALS-fast), 52.2 (ALS-slow) N/A
C8B F5GY80 Zubiri et al. 2018 Late ALS (ALS fast cohort) Early ALS (ALS fast cohort) Plasma Up 6 ALS-fast, 6 ALS-slow 61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow) N/A N/A
C8B P07358 Vu et al. 2023 ALS fast ALS slow CSF Up 6 ALS-fast, 5 ALS-slow 54.3 (ALS-fast), 43.4 (ALS-slow) 55.3 (ALS-fast), 52.2 (ALS-slow) N/A
C8A P07357 Collins et al. 2015 ALS Control CSF Up 90 ALS, 80 control N/A N/A N/A
C8A P07357 Vu et al. 2023 ALS fast ALS slow CSF Up 6 ALS-fast, 5 ALS-slow 54.3 (ALS-fast), 43.4 (ALS-slow) 55.3 (ALS-fast), 52.2 (ALS-slow) N/A
C7 P10643 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
C7 P10643 Zubiri et al. 2018 Late ALS (ALS fast and ALS slow cohort) Early ALS (ALS fast and ALS slow cohort) Plasma Up 6 ALS-fast, 6 ALS-slow 61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow) N/A N/A
C7 P10643 Zubiri et al. 2018 Late ALS (ALS slow cohort) Early ALS (ALS fast cohort) Plasma Up 6 ALS-fast, 6 ALS-slow 61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow) N/A N/A
C7 P10643 Katzeff et al. 2020 ALS Control Serum Down 28 ALS, 22 control N/A 52.7 N/A
C7 P10643 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
C6 P13671 Leoni et al. 2019 BO-ALS LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
C6 P13671 Zhou et al. 2023 SO-ALS Control CSF Down 4 BO-ALS, 5 SO-ALS, 5 control 63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS) 64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS) N/A
C6 P13671 Vu et al. 2023 ALS fast ALS slow CSF Up 6 ALS-fast, 5 ALS-slow 54.3 (ALS-fast), 43.4 (ALS-slow) 55.3 (ALS-fast), 52.2 (ALS-slow) N/A
C6 P13671 Zhou et al. 2023 BO-ALS SO-ALS CSF Up 4 BO-ALS, 5 SO-ALS, 5 control 63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS) 64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS) N/A
C5 P01031 Xu et al. 2018 ALS Control Plasma Up 42 ALS, 18 control N/A 61.8 ± 9.6 N/A
C5 P01031 Collins et al. 2015 ALS Control CSF Up 90 ALS, 80 control N/A N/A N/A
C5 P01031 Vu et al. 2023 ALS fast ALS slow CSF Up 6 ALS-fast, 5 ALS-slow 54.3 (ALS-fast), 43.4 (ALS-slow) 55.3 (ALS-fast), 52.2 (ALS-slow) N/A
C4BPB P20851 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
C4BPA P04003 Zubiri et al. 2018 ALS fast (early stage) ALS slow (early stage) Plasma Up 6 ALS-fast, 6 ALS-slow 61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow) N/A N/A
C4BPA P04003 Vilardo et al. 2024 ALS (discovery cohort) Control (discovery cohort) Plasma EVs Up 61 ALS, 30 control N/A 62.88 ± 12.60 N/A
C4B_2 E5RGG2 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
C4B P0C0L5 Leoni et al. 2019 BO-ALS LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
C4B P0C0L5 Zhou et al. 2023 SO-ALS Control CSF Down 4 BO-ALS, 5 SO-ALS, 5 control 63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS) 64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS) N/A
C4B P0C0L5 Oeckl et al. 2020 ALS Control CSF Up 26 ALS, 16 control N/A N/A N/A
C4A P0C0L4 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
C4A P0C0L4 Xu et al. 2018 ALS Control Plasma Up 42 ALS, 18 control N/A 61.8 ± 9.6 N/A
C4A P0C0L4 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
C3 P01024 Umoh et al. 2018 ALS Control Frontal cortex Down 19 ALS, 10 control 55 59 10.6
C3 P01024 Collins et al. 2015 ALS Control CSF Up 90 ALS, 80 control N/A N/A N/A
C3 P01024 Vu et al. 2023 ALS fast ALS slow CSF Up 6 ALS-fast, 5 ALS-slow 54.3 (ALS-fast), 43.4 (ALS-slow) 55.3 (ALS-fast), 52.2 (ALS-slow) N/A
C3 P01024 Leoni et al. 2019 BO-ALS LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
C2 P06681 Collins et al. 2015 ALS Control CSF Up 90 ALS, 80 control N/A N/A N/A
C2 B4DQI1 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
C2 P06681 Vu et al. 2023 ALS fast ALS slow CSF Up 6 ALS-fast, 5 ALS-slow 54.3 (ALS-fast), 43.4 (ALS-slow) 55.3 (ALS-fast), 52.2 (ALS-slow)
C1S P09871 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
C1S C9IZP8 Collins et al. 2015 ALS Control CSF Up 90 ALS, 80 control N/A N/A N/A
C1RL Q9NZP8 Vu et al. 2023 ALS fast ALS slow CSF Up 6 ALS-fast, 5 ALS-slow 54.3 (ALS-fast), 43.4 (ALS-slow) 55.3 (ALS-fast), 52.2 (ALS-slow) N/A
C1R P00736 Zhou et al. 2023 BO-ALS Control CSF Down 4 BO-ALS, 5 SO-ALS, 5 control 63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS) 64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS) N/A
C1R P00736 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
C1QTNF5 Q9BXJ0 Zhou et al. 2023 SO-ALS Control CSF Down 4 BO-ALS, 5 SO-ALS, 5 control 63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS) 64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS) N/A
C1QC P02747 Hayashi et al. 2020 ALS Control CSF exosome-enriched fractions Down 3 ALS, 3 control N/A 74.3 N/A
C1QC P02747 Xu et al. 2018 ALS Control Plasma Up 42 ALS, 18 control N/A 61.8 ± 9.6 N/A
C1QC P02747 Zhou et al. 2023 SO-ALS Control CSF Down 4 BO-ALS, 5 SO-ALS, 5 control 63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS) 64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS) N/A
C1QC P02747 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
C1QC P02747 Vilardo et al. 2024 ALS (discovery cohort) Control (discovery cohort) Plasma EVs Up 61 ALS, 30 control N/A 62.88 ± 12.60 N/A
C1QBP I3L3Q7 Leoni et al. 2019 BO-ALS LO-ALS PBMCs Up 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS) N/A N/A
C1QB P02746 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
C1QB P02746 Zhou et al. 2023 SO-ALS Control CSF Down 4 BO-ALS, 5 SO-ALS, 5 control 63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS) 64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS) N/A
C1QA P02745 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
C1QA P02745 Bereman et al. 2018 ALS Control CSF Up 33 ALS, 30 control N/A N/A N/A
C1orf123 Q9NWV4 Englen-Lee et al. 2017 ALS Control Spinal cord (PH & AH) Up 10 ALS, 10 control 57.6 ± 10.9 62.6 ± 10.6 N/A
C19orf70 Q5XKP0 Seyfried et al. 2018 ALS Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
C19orf10 Q969H8 Zhou et al. 2023 BO-ALS Control CSF Down 4 BO-ALS, 5 SO-ALS, 5 control 63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS) 64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS) N/A
C18orf8 Q96DM3 Oeckl et al. 2020 ALS Control Spinal cord Up 8 ALS, 7 control N/A 59 (52-61) 36 (24-90)
C16orf89 Q6UX73 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
C12orf49 Q9H741 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
C11orf58 E9PRZ9 Leoni et al. 2019 BO-ALS LO-ALS PBMCs Down 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS) N/A N/A
BTF3 P20290 Guise et al. 2024 ALS Control Spinal cord (SMNs) Down 3 ALS, 3 control N/A 69.3 9.2
BTF3 P20290 Iridoy et al. 2018 ALS Control Spinal cord (AH) Up 9 ALS, 8 control 57.6 62.8 N/A
BTD P43251 Chen et al. 2016 ALS Control CSF Down 35 ALS, 10 control N/A 52.7 ±12.13 N/A
BTD P43251 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
BST1 A6NC48 Vassileff et al. 2020 ALS Control Motor Cortex EVs Down 7 ALS, 3 control N/A N/A N/A
BSG P35613 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A